Active substance:
Each chewable tablet contains:
Carprofen 50 mg
Excipients:
Liver flavour liquid 2.5 mg
Special dry flavour vegetarian 25 mg
PHARMACEUTICAL FORM
Chewable tablet
Beige-brown tablets with a break-line.
The chewable tablet can be divided in two equal halves.
Indications for use, specifying the target species
Reduction of inflammation and pain caused by acute and chronic musculoskeletal disorders (e.g. osteoarthritis). As a follow up to parenteral analgesia in the management of post operative pain.
Contraindications
Do not use in cats.
Do not use in pregnant or lactating bitches.
Do not use in cases of hypersensitivity to active substance, to other NSAIDs and to any of the excipients.
Do not use in animals suffering from cardiac, hepatic or renal disease, where there is a possibility of gastrointestinal ulceration or bleeding or where there is evidence of a blood dyscrasia.
Special precautions for use
Special precautions for use in animals
Use in dogs less than 6 weeks of age, or in aged dogs may involve additional risk. If such use cannot be avoided, such dogs may require a reduced dosage and careful clinical management.
Due to the good palatability of the chewable tablet, they should be stored in a safe place out of the reach of animals. Intake of doses exceeding the recommended number of chewable tablets may lead to severe adverse effects. If this is the case, seek veterinary assistance immediately.
Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity.
Concurrent administration of potential nephrotoxic drugs should be avoided.
NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated.
Do not administer other NSAIDs and glucocorticoids concurrently or within 24 hours of each other.
Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs which can lead to toxic effects.
Exposure to intense light during treatment may lead to photodermatitis in animals with low skin pigmentation. Such adverse reactions with carprofen have occurred in laboratory animals and humans. Although skin reactions of this kind have not yet been observed in dogs, they cannot be ruled out at present.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
Persons administering the product should avoid direct contact between the skin and the active substance as phototoxic reactions may occur in humans under certain circumstances and there is a risk of photoallergy development which may persist for a number of years in the form of severe photosensitivity with reddening, swelling and formation of blisters on the skin.
Laboratory studies have proven that carprofen has photosensitising properties, as do other NSAIDs. Neither in dogs nor in humans has photodermatitis, which may persist over a number of years as severe photosensitivity with reddening, swelling and formation of blisters on the skin, been reported following the administration of Dolocarp chewable tablets. Nevertheless, such skin reactions cannot be completely ruled out. Wash hands after handling the product. In case of accidental ingestion, seek medical advice immediately and show the package leaflet to the physician.
Amounts to be administered and administration route
Chewable tablet for oral use. The stated dose should not be increased.
Administer the dose of 4.0 mg per kg body weight once daily. In cases of long term treatment the initial dose may, subject to clinical response, be reduced to 2 mg per kg body weight once daily.
Most dogs will voluntarily ingest Dolocarp chewable tablets.
The treatment period depends on the clinical development of the disease. Long-term treatment should only be performed under veterinary supervision.
The tablets can be broken along the breakline.
